DBCO-PEG4-Ahx-DM1 |CAS 2479378-44-2|DC Chemicals

Cas No.:	2479378-44-2
Chemical Name:	DBCO-PEG4-Ahx-DM1
SMILES:	COC1=CC(C/C(C)=C/C=C/[C@@H](OC)[C@]2(O)NC(OC([C@@H](C)C(O3)[C@]3(C)[C@@H](OC([C@H](C)N(C)C(CCCCCNC(CCOCCOCCOCCOCCNC(CCC(N4CC(C=CC=C5)=C5C#CC6=C4C=CC=C6)=O)=O)=O)=O)=O)CC7=O)C2)=O)=CC(N7C)=C1Cl
Formula:	C₆₈H₈₉ClN₆O₁₇
M.Wt:	1297.92
Purity:	>95%
Sotrage:	2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO

Description:

DBCO-PEG4-Ahx-DM1 is a drug-linker conjugate composed of a potent microtubulin inhibitor DM1 and a linker DBCO-PEG4-Ahx to make antibody drug conjugate (ADC). Mertansine (DM1) is a microtubulin inhibitor and is an antibody-conjugatable maytansinoid that is developed to overcome systemic toxicity associated with maytansine and to enhance tumor-specific delivery.

MSDS

COA

LOT NO.	DOWNLOAD

2018-0101

Cat. No.	Product name	Field of application
DC57082	MC-MMAE	Mc-MMAE is a protective group (maleimidocaproyl)-conjugated monomethyl auristatin E (MMAE), which is a potent tubulin inhibitor. Mc-MMAE is a drug-linker conjugate for ADC.
DC46408	Gly3-VC-PAB-MMAE	Gly3-VC-PAB-MMAE consists a cleavable ADC linker (Gly3-VC-PAB) and a potent tubulin inhibitor (MMAE). Gly3-VC-PAB-MMAE can be used in the synthesis of antibody-drug conjugates (ADCs).
DC46199	DBCO-PEG4-Ahx-DM1	DBCO-PEG4-Ahx-DM1 is a drug-linker conjugate composed of a potent microtubulin inhibitor DM1 and a linker DBCO-PEG4-Ahx to make antibody drug conjugate (ADC). Mertansine (DM1) is a microtubulin inhibitor and is an antibody-conjugatable maytansinoid that is developed to overcome systemic toxicity associated with maytansine and to enhance tumor-specific delivery.
DC10159	N3-PEG3-vc-PAB-MMAE	N3-PEG3-vc-PAB-MMAE is a drug-linker conjugate for ADC with potent antitumor activity by using the anti-mitotic agent, monomethyl auristatin E (MMAE), linked via the peptide N3-PEG3-vc-PAB.
DC10120	MC-Val-Cit-PAB	MC-Val-Cit-PAB, also known as MC-Val-Cit-PAB-OH, is a cathepsin cleavable ADC peptide linker. MC-Val-Cit-PAB is useful for making ADC conjugate (antibody-drug conjugate). FDA approved drugs such as brentuximab vedotin used this linker.